---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Prevalence"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Prevalence. Topics: Benign and malignant insulinoma, Japan, 2017 to 2018: nationwide survey prevalence; Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey of treated patients; Non-islet cell tumor hypoglycemia: review estimate of prevalence relative to insulinoma; Gastrointestinal stromal tumor, Japan, 2011 to 2023: hypoglycemia from any cause and NICTH at one institution; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/prevalence"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Tumor hyperinsulinism

<a id="topic-2.2.1.2.2-1"></a>

### Benign and malignant insulinoma, Japan, 2017 to 2018: nationwide survey prevalence

> “A nationwide, questionnaire‐based survey was carried out to determine the number of patients with EHH who were treated for hypoglycemia or hypoglycemia‐related complications in 2017−2018.”
> “205 with insulinoma (118 benign, 18 malignant and 69 unknown subtype)”
> “The estimated prevalence was 0.16 per 100,000 population.”
> “insulinoma was more prevalent among female patients than among male patients (140/65), although the sex difference was smaller in those with malignant cases (10/8).”
> “compared with the pediatric clinics, the response rate from the adult clinics was lower (68.1% vs 38.2%), which might have affected the estimated prevalence of each EHH disorder.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

<a id="topic-2.2.1.2.2-2"></a>

### Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey of treated patients

> “Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.”
> “A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010.”
> “Non-functioning tumor (NF)-PNETs comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%).”

Source: [Ito et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24499825/)

<a id="topic-2.2.1.2.2-3"></a>

### Non-islet cell tumor hypoglycemia: review estimate of prevalence relative to insulinoma

> “The true prevalence and clinical impact of hypoglycaemia induced by NICTH remains uncertain in the current medical literature. However, it is estimated to be four times less prevalent than insulinoma.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.2.2-4"></a>

### Gastrointestinal stromal tumor, Japan, 2011 to 2023: hypoglycemia from any cause and NICTH at one institution

> “Eight patients out of 195 patients met this criteria (4.1%). The causes of hypoglycemia were diverse, including tumor growth, adverse drug effects, post-operation, liver failure, and unknown”
> “Hypoglycemia was observed in 4.1% of patients with GISTs (all stages) and 14.2% of patients with unresectable/metastatic GISTs.”
> “The present study identified 1 case with recurrent hypoglycemia due to NICTH.”

Source: [Chida et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11465228/)

<a id="topic-2.2.1.2.2-5"></a>

### Malignant insulinoma, United States, October 2026: company point-in-time estimate from claims data

> “~2,500 Addressable Malignant Insulinoma Patients in the U.S.”
> “Malignant insulinoma patients (includes C25.4, hypoglycemia, CGM, supporting symptoms”
> “The ICD-10 code C25.4 is for malignant neoplasm of the endocrine pancreas, or cancer of the endocrine pancreas”
> “Point-in-time prevalence as of Oct 2026. Source: Veeva Compass database; covers more than 70% of US patients, 4M+ providers, 120B+ records, and 8+ years of patient history.”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.2.2-6"></a>

### Non-islet cell tumor hypoglycemia, United States, October 2026: company point-in-time estimate from claims data

> “~1,500 Addressable NICTH Patients in the U.S.”
> “Dextrose, oral glucocorticoids, and glucagon (diazoxide and somatostatin analogs are not effective treatments for hypo from IGF-2 tumors)”
> “Point-in-time prevalence as of Oct 2026.”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.2.2-7"></a>

### Tumor hyperinsulinism, United States: company total of about 4,000 patients

> “Tumor HI: ~4,000 patients; $4-5B TAM”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
